Compare CLOV & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLOV | DBVT |
|---|---|---|
| Founded | 2014 | 2002 |
| Country | United States | France |
| Employees | N/A | 90 |
| Industry | Medical Specialities | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2020 | 2014 |
| Metric | CLOV | DBVT |
|---|---|---|
| Price | $2.17 | $20.98 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 7 |
| Target Price | $2.90 | ★ $32.04 |
| AVG Volume (30 Days) | ★ 5.1M | 232.4K |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.03 | 10.26 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,924,308,000.00 | $5,636,000.00 |
| Revenue This Year | $52.59 | $79.21 |
| Revenue Next Year | $15.37 | $1,754.26 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 40.34 | 35.77 |
| 52 Week Low | $1.58 | $7.53 |
| 52 Week High | $3.92 | $26.19 |
| Indicator | CLOV | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 68.31 | 49.49 |
| Support Level | $2.12 | $19.64 |
| Resistance Level | $2.25 | $24.47 |
| Average True Range (ATR) | 0.10 | 1.17 |
| MACD | 0.05 | 0.12 |
| Stochastic Oscillator | 91.41 | 43.68 |
Clover Health Investments Corp is a healthcare technology company. It focuses on empowering Medicare physicians to proactively manage chronic diseases through its proprietary software platform, Clover Assistant. This cloud-based solution provides personalized insights to physicians, enabling early detection and management of chronic conditions. It operates in one segment: Insurance, through which it offers PPO and HMO plans to Medicare Advantage members in several states.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.